In the bio-tech market, noteworthy events have occurred within the operations of **Amcor Plc (AMCR)**. To begin, a bull case for the company has been presented, its stock is seen as a favorite among dividend value stocks boasting a 21% return on equity, and it's considered as a quality stock. While institutions own 48% of the company, individual investors are its largest shareholders with 51% ownership. Furthermore, its stocks have risen and seen heavy insider buying despite weak volumes and dividend concerns. Jefferies initiated a 'buy' rating for Amcor, setting the price target at $12 due to its strong market position. Reportedly, **Amcor's stock** is underperforming in the consumer discretionary sector, but opportunist projections remain. Meanwhile, the company boosted its PCR capabilities with the latest investment in Kentucky. Recently, Amcor made a proposed expansion by merging with **Berry Global**. The merger was approved and anticipates doubling cash flows, with the stock nearing all-time lows. Amcor has been denoted as a valuable buying opportunity, offering a strong yield and potential for massive growth, yet concerns prevail post partnership with a Slovenian Manufacturer.
Amcor Plcs AMCR News Analytics from Mon, 29 May 2017 04:31:08 GMT to Fri, 18 Jul 2025 12:08:36 GMT -
Rating 7
- Innovation 6
- Information 5
- Rumor -2
